Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19

Exclusion Criteria

• •Patients who cannot provide informed consent
• •History of surgery involving CN V, VII, IX, or X.
• •Patient on chronic renal dialysis
• •Patients with history of solid organ transplant
• •Patients with underlying seizures disorder
• •Patients with a cardiac pacemaker
• •Patients with any implanted electrical device
• •Patients with dermatologic conditions affecting the ear, face, or neck region (i.e. psoriasis), or with cuts or abrasions to the external ear that would interfere with needle placement
• •Patients with hemophilia or other bleeding disorders
• •Patients who are pregnant or breastfeeding
• •Patients with active TB infection
• •Patient already on mechanical ventilation or ECLS
• •Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
• •In the opinion of the investigator, progression to mechanical ventilation, ECLS or death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
• •Participating in other drug clinical trials
• •ALT or AST \> 5 x ULN detected within 24 hours at screening or at baseline (according to local laboratory reference ranges)
• •ANC \< 500/µL at screening and baseline (according to local laboratory reference ranges)
• •Platelet count \< 50,000/µL at screening and baseline (according to local laboratory reference ranges)
• •Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study